Elizabeth Trehu Biography and Net Worth

Elizabeth (Beth) Trehu, M.D., FACP, brings to Jounce more than 30 years of clinical experience, including 20 years in the biotech industry leading translational and integrated hematology and oncology drug development. Dr. Trehu designed and ran her first immunotherapy cancer trials in the early 90’s as a fellow and assistant professor of medicine at Tufts University School of Medicine, where she conducted preclinical and clinical research in immunotherapy with the NCI Cytokine Working Group. Dr. Trehu joined Jounce from Promedior, Inc., where she served as the chief medical officer. In this role, she led the creation and implementation of clinical development plans for Promedior’s lead macrophage product candidate, PRM-151, which led to the acquisition of Promedior by Roche in 2020. Prior to Promedior, Dr. Trehu served as vice president, oncology product development and medical affairs for Infinity Pharmaceuticals, and earlier, held various leadership positions at Genzyme Corporation, including vice president and general manager of hematology for Genzyme’s transplant oncology group, where she had global responsibility for Clolar®, Campath®, and Fludara®. Earlier in her career, Dr. Trehu held roles of increasing responsibility at Millennium Pharmaceuticals, including vice president, oncology global medical affairs, and was integral in the development and commercialization of VELCADE®. She was an internal medicine resident and chief resident at Georgetown University School of Medicine, where she also ran the transitional residency program.  Dr. Trehu received her A.B. cum laude in English Literature from Princeton University and her M.D. from New York University School of Medicine.

Dr. Trehu has served on the Board of Directors of Constellation Pharma, Inc. since 2018, where she is a member of the Research and Development Committee and Compensation Committee.